Kornimate/medical-research-clean huggingface dataset:
adaptive and trained immunity in the pathogenesis of igg4-related disease

Conditions: IgG4 Related Disease

Summary: enquire involvement of trained immunity in the pathogenesis of igg4rd

enquire involvement of trained immunity in the pathogenesis of igg4rd using primary macrophages and co-cultures with patient derived fibroblasts. the investigators will first assess whether macrophages from patients are trained compared to macrophages of healthy controls and then challenge them with igg from igg4rd patients to evaluate the functional effects on cultivated fibroblasts.

Eligibility criteria:
inclusion criteria: patients: * adult subjects \> or = 18 years of age * subjects capable of providing informed consent * active igg4-rd based on the igg4-related disease activity index * fulfillment of the 2019 acr/eular classification criteria for igg4rd healthy controls: * adult subjects \> or = 18 years of age * subjects capable of providing informed consent exclusion criteria: patients and healthy controls: * subjects \< 18 years of age * pregnant women * comorbidities (other ongoing active autoimmune diseases, ongoing cancer, ongoing infections) * ongoing immunosuppressive therapy

Keywords: trained immunity
the use of the 25 (oh) d saliva test as a substitute for the 25 (oh) d serum test in healthy people

Conditions: Nutritional Deficiency

Summary: routine examination of vitamin d levels is carried out by checking serum 25 (oh)d levels, which indicate circulating vitamin d levels. while serum 1.25 (oh) d levels are less frequently utilized, they represent the active form of vitamin d and could be a substitute for checking vitamin d levels. this study aims to find the correlation between vitamin d levels, namely 25 (oh) d and 1.25 (oh) d saliva, which correlate with serum 25 (oh) d and 1.25 (oh) d levels in the examination of salivary vitamin d, and which could be a substitute for checking serum vitamin d levels.

routine examination of vitamin d levels is carried out by checking serum 25 (oh)d levels, which indicate circulating vitamin d levels. while serum 1.25 (oh) d levels are less frequently utilized, they represent the active form of vitamin d and could be a substitute for checking vitamin d levels.this study aims to find the correlation between vitamin d levels, namely 25 (oh) d and 1.25 (oh) d saliva, which correlate with serum 25 (oh) d and 1.25 (oh) d levels in the examination of salivary vitamin d, and which could be a substitute for checking serum vitamin d levels.this study is a cross-sectional study involving healthy men and women, aged 20-50 years, from lima puluh village, batubara district, north sumatra province, indonesia. the parameters studied were 25 (oh) d and 1.25 (oh) d levels of saliva and serum.

Eligibility criteria:
inclusion criteria: * men and women aged 18-60 years, not currently experiencing chronic pain, kidney problems, liver problems, or other hormone disorders. exclusion criteria: * subjects who consumed vitamin d supplements regularly, were pregnant, or were breastfeeding.

Keywords: vitamin d cross-sectional non-invasive correlation deficiency insufficiency
a brief marijuana intervention for adolescent women - 1

Conditions: Marijuana Abuse; Sexual Risk Behaviors

Summary: the purpose of this study is to examine the efficacy of a brief motivational intervention on marijuana use and sex-risk behavior in young women.

this study holds the promise of developing a brief, efficacious intervention to reduce marijuana use and related sexual risk-taking behavior among the large populaton of late adolescent women who are regular marijuana users. in the abscence of intervention, these women are at heightened risk of contracting hiv and other sexually transmitted infections. therefore it is crucial to develop an intervention that will reduce their marijuana and subsequent sexual risk taking behavior. the intervention employed in this study represents a novel adaptation of interventions that are well-supported with similar populations. if the current intervention is found to be efficacious, it can be readily integrated into a variety of treatment settings, particularly other primary care settings. in addition, this study will contribute valuable information about the relationship between marijuana use and sexual risk taking behavior and about the mechanisms of change in marijuana use in late adolescent women. comparison(s): participants will be assigned, in this 6 month longitudinal study, to an assessment-only group or an assessment plus intervention group. those in the intervention group will receive 2 motivational intervention sessions during the first 3 months of their study participation.

Eligibility criteria:
inclusion criteria: current marijuana use; currently sexually active; able to complete the study procedures in english exclusion criteria: pregnant; alcohol dependence; drug dependence

Keywords: marijuana sexual risk
evaluation of zk 6032924 in probable alzheimer's disease patients versus healthy volunteers and the radiation dosimetry of zk 6032924 in healthy volunteers

Conditions: Positron-Emission Tomography; Alzheimer's Disease

Summary: pet (positron emission tomography) imaging with bay85-8101 (zk 6032924) in patients with alzheimer's disease compared to healthy volunteers.


Eligibility criteria:
inclusion criteria:patients for brain imaging:- patient and designee capable of giving fully informed consent in writing- patient fulfils dsm-iv and nincds-adrda criteria for probable alzheimer's disease. other forms of dementia excluded- males or postmenopausal females aged \>/= 50 yearshealthy volunteers for brain imaging: - able to give fully informed consent in writing- absence of any sign of dementia/cognitive impairment in neuropsychological examinations- males or postmenopausal females aged \>/= 50 years healthy volunteers for whole body imaging:- able to give fully informed consent in writing - males or postmenopausal females aged \>/= 60 years - no significant disease or drug use exclusion criteria:for all healthy volunteers and patients:- any disease, condition, or concomitant medications that significantly compromises the function of the body systems and could result in excessive accumulation, impaired metabolism, altered excretion of the radiotracer, or might interfere with the conduct of the study or interpretation of the results

Keywords: alzheimer's disease diagnostic imaging neuroinflammation pet diagnosis pet tracer
use of an ocular telemetry sensor in diamox treated patients

Conditions: Glaucoma; Ocular Hypertension

Summary: a soft contact lens integrating a sensor is placed on subjects with high intraocular pressure (iop) after administration of an iop-lowering drug to investigate the device's capacity to detect the induced iop reduction.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of glaucoma or ocular hypertension * iop of ≥ 15 mmhg. * patients of either gender. * older than 18 years. * patients who accept signing an informed consent approved by the ethics committee. exclusion criteria: * patients not able to understand the nature of the research * patients under tutorship * corneal abnormalities in both eyes * subjects with contraindications for wearing contact lenses * history of ocular surgery within the last 3 months * known hypersensitivity to diamox® or to any of its excipients * pregnancy and lactation * simultaneous participation in other clinical research * patients with evidence of ocular infection or inflammation * history of renal or hepatic impairment, hypokalemia and hyponatremia

Keywords: glaucoma and ocular hypertension patients
genetic basis of pacing-induced cardiomyopathy

Conditions: Pacemaker, Artificial; Cardiomyopathies

Summary: the purpose of this study is to collect a saliva sample from patients with a pacemaker to study genes involved in cardiomyopathy, a condition where the heart muscle is abnormal.

dna will be extracted from the saliva to test for changes in genes related to cardiomyopathy.

Eligibility criteria:
inclusion criteria: * patients who have been assessed for cardiomyopathy exclusion criteria: * patients who do not have adequate follow up care to determine if they do or do not have cardiomyopathy
a randomized, double-blind, placebo-controlled study of droxidopa for fatigue in parkinson's disease

Conditions: Parkinson Disease; Fatigue; Parkinsonism

Summary: this is a randomized, double-blind, placebo-controlled trial comparing droxidopa to placebo for fatigue in parkinson's disease. the primary outcome measure is change in the parkinson's disease fatigue scale, a 16-item scale that measures the physical effects of fatigue as well as the impact of fatigue on daily functioning and activities, including socialization. secondary outcomes are the pdq-39, a 39-item self-report questionnaire assessing parkinson's disease-specific health related quality over the last month in 8 different dimensions of function and well-being, and the epworth sleepiness scale, a questionnaire querying 8 situations for which the subject will rate the likelihood of falling asleep. there will be a screening visit (sc), baseline visit (bl), 2 clinic visits at 6 and 12 weeks (v01, v02), and telephone contact at 4 weeks and 8 weeks (t1, t2). in-person visits will include review of informed consent, concomitant medication review, adverse event review, pill counts, vital signs (including supine blood pressure), and outcome measurements. telephone visits will include review of informed consent, concomitant medication review, and adverse event review.


Eligibility criteria:
inclusion criteria: * diagnosis of parkinson's disease * have normal kidney function (determined at screening visit by blood sample analysis), and no active medical diagnoses associated with fatigue * no orthostatic symptoms (i.e. light headedness, blurred vision, and/or muscle weakness) * no objective orthostasis (significant drop in blood pressure when standing) * no supine hypertension (high blood pressure while laying down) judged to be of clinical significance by the investigator * well-controlled depression * stable dopaminergic medication regimen for 6 weeks prior to screening * no concurrent use of fludrocortisone, midodrine, or other medications that may raise blood pressure * pd fatigue scale score of 50 or above exclusion criteria: * diagnosis of atypical parkinsonism (having symptoms that mimic pd without a pd diagnosis) * prior intolerance of droxidopa * snri or tca class (both antidepressant) medications (irrespective of indication) * use of activating agents (amantadine, modafinil, methylphenidate and related stimulants) * significant cardiac disease history * significant kidney disease history, or creatinine (a chemical found in the blood) greater than 1.5 mg/dl at baseline * poorly controlled depression * women who are pregnant or breastfeeding * significant history of gastro intestinal disease that may interfere with absorption (gastric bypass, inflammatory bowel disease)
40 hz transcranial alternating current stimulation for inducing gamma oscillations

Conditions: Alzheimer Disease; Cognitive Decline

Summary: this study aims to compare the efficacy of different 40 hz tacs protocols in entraining gamma oscillations, which are linked to various cognitive functions and play a significant role in cognitive impairments like alzheimer's disease. specifically, it examines the effects of 40 hz tacs applied to frontal brain regions versus fronto-temporal regions on gamma oscillations and working memory in healthy elderly individuals.


Eligibility criteria:
inclusion criteria: * healthy elderly between 50-80 years of age * normal or corrected to normal eye vision * right-handed * non-smokers * at least 70 % accuracy in working memory training task exclusion criteria: * history of neurological or psychiatric disorders including seizures or epilepsy, * taking cns, blood pressure and other medications * having metal implants in the head and neck * significant cognitive decline meassured by the montreal cognitive assessment (moca)
safety and efficacy study of mre0094 to treat chronic, neuropathic, diabetic foot ulcers

Conditions: Foot Ulcer, Diabetic; Diabetes Complications

Summary: this is a clinical research study of an experimental topical drug for the treatment of chronic, neuropathic, diabetic foot ulcers. patients participating in the study may receive an active drug (mre0094), inactive drug (placebo), or a gel used to treat diabetic foot ulcers currently available for sale in the united states. what treatment a patient will receive is determined by chance (like drawing a number from a hat). all patients will receive additional care for diabetic foot ulcers during the study. participation in the study can be up to 4½ months.


Eligibility criteria:
inclusion criteria: participants included in the study must: * have type 1 or type 2 diabetes mellitus. * have problems with the nerves in their feet. * have an ulcer on the bottom surface of their foot that has been present for 3 weeks or more and is of sufficient size to qualify for the study. * be able to apply study drug to their ulcer, or have a caregiver do it. * be able to visit the doctor regularly during the 4½ month study. exclusion criteria: participants may not participate in the study if: * their ulcer is caused by bad blood flow to their foot. * their ulcer is infected. * they cannot wear a special boot during the study to take pressure off the ulcer. * they have certain other diseases, or are using certain types of drugs.

Keywords: toe ulcer heel ulcer foot ulcer diabetic feet diabetic foot complications of diabetes
a study of dedn6526a in patients with metastatic or unresectable melanoma

Conditions: Malignant Melanoma

Summary: this multicenter, open-label study will assess the safety and pharmacokinetics of dedn6526a in patients with metastatic or unresectable melanoma. cohorts of patients will receive escalating doses of dedn6526a by intravenous infusion on day 1 of each 21-day cycle. in the absence of disease progression or unacceptable toxicity, patients may continue to receive dedn6552a for up to 17 cycles (1 year).


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 years of age * eastern cooperative oncology group (ecog) performance status 0 or 1 * histologically confirmed metastatic melanoma (ajcc stage iv) or unresectable melanoma (ajcc stage iii) * prior failure of \>/= 1 prior treatment regimens for metastatic or unresectable melanoma due to disease progression or unacceptable toxicity and for whom no standard therapy is available * measurable disease according to recist criteria * adequate bone marrow, liver and renal function * female patients of childbearing potential and male patients with female partners of childbearing potential must agree to use one highly effective form of non-hormonal contraception or two effective forms of non-hormonal contraception through the course of the study treatment and for 6 months after the last dose of study treatment exclusion criteria: * treatment with cytotoxic or antibody based therapy within 21 days prior to first dose of study treatment, or with any other anti-cancer therapy within 5 half-lives of the therapy prior to first dose of study treatment * known active infection (including hiv and atypical mycobacterial disease, but excluding fungal infection of the nail beds) * current grad \>/= 2 toxicity (except alopecia or anorexia) from prior therapy * grade \>/= 2 peripheral neuropathy * history of severe allergic or anaphylactic reactions to monoclonal antibody therapies (or recombinant antibody-related fusion proteins) * clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis * untreated or active central nervous system (cns) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control) * evidence of significant uncontrolled concomitant disease or disorder * pregnant or lactating women * prior treatment with any other antibody-drug conjugate (adc) compound containing monomethyl auristatin e (mmae) for the treatment of melanoma * previous participation in a clinical trial within 30 days of the day of first study drug administration (cycle 1, day 1)
sour taste and cold temperature in dysphagia

Conditions: Stroke

Summary: the objective is to establish the effect of sour taste and cold temperature on the pharyngeal swallowing transit time after ischemic hemisphere stroke.

over the past decade there were many studies over normal and pathological swallowing that discuss the influence of taste and temperature. nevertheless there were many questions on the issue that remains to be solved, including the hemispheric lateralization of lesions dysphagic patients remains also to be fully understood.swallowing disorder is defined as oropharyngeal dysphagia in presence of alterations in any phase of the complex swallowing dynamics. it could be congenital or acquired, affecting nutritional aspects, hydration, lung function and the individual's social integration \[1\]. stroke, has a high incidence among neurological diseases, and cause disturbs on swallowing dynamics presenting signs of dysphagia in at least 50% of cases.a study that analyzed swallowing dynamics by videofluoroscopy in individuals with history of one or more stroke episodes with oropharyngeal dysphagia shows shorter pharyngeal and oropharyngeal transit times with cold stimulus than without them. other study of heterogeneous neurological diseases such as cerebral palsy, brain trauma, stroke, and alzheimer's disease, concluded that sour taste improved swallowing, minimizing laryngotracheal penetration and aspiration in individuals with neurological damaged. chen et al. in an analysis of 42 healthy individuals with several taste bolus found that awareness and arousal could also influence the swallowing function.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of stroke exclusion criteria: * instability clinic

Keywords: stroke; sour taste; cold temperature; pharyngeal swallowing
surgical excision and intralesional steroid injection for prevention of post caesarean keloid recurrence

Conditions: Keloid

Summary: two groups of patients (73 patients each) undergoing routine caesarean section has recurrent keloid at site of surgical scar. one group will undergo surgical excision of keloid. the other group will have combined surgical excision of keloid and single intralesional dexamethasone injection at edges of wound.all patients were reviewed once per month for 6 months for evidence of recurrence

one hundred forty six patients that are admitted at kasr al aini teaching university hospital for caesarean section, will be enrolled in this randomized clinical trial after approval by the local ethical health committee. a written informed consent will be obtained from each participant after full explanation of the procedure. under general or spinal anaesthesia done routinely during caesarean section, total extralesional surgical excision of the keloid is performed and minimal undermining followed by the usual steps of caesarean section. primary closure of the wound in layers is achieved in all cases. a running subcuticular prolene 2/0 stitch is used to suture the skin. group a of 73 patients will not receive further injection. in 73 patients (group b), the wound edges are injected once with dexamethasone. a 1 ml syringe with a 30-gauge needle is used and injection is both intradermal and subdermal. repeated alternate punctures are used to bathe the wound edges with the drug. approximately 0.5-1 ml of dexamethasone (4 mg/ml) in wound tissue. for all patients, the wound is painted with betadine and sealed until postoperative day 14, at which time the subcuticular stitch is removed. postoperative medications are given to all patients in the form of analgesics and antibiotics as routinely given at the hospital. all patients were advised to avoid direct sun exposure for the following month. no postoperative applications (eg, compression, steroid injections, etc) were used in any of the patients. all patients were reviewed once per month for 6 months.

Eligibility criteria:
inclusion criteria: * documented keloids of pfannenstiel incision or midline subumbilical incision of one to five years duration. * previous treatment of keloid and recurrence. * patient complaint of cosmetic disfiguring, pain or pruritis at site of scar. exclusion criteria: * scar \<1 years' duration * scar extending beyond the limits of the original lesion * postburn keloids * diabetes mellitus, anaemia (haemoglobin level \<10mg/dl), malignancy, malnutrition. * local inflammation at site of scar * allergy to dexamethasone. * immunocompromized patients or patients on chronic steroid treatment.

Keywords: recurrent keloid surgical excision steroids injection
cardiovascular risk factors in rheumatoid arthritis patients ( comparison between seronegative and seropositive cases )

Conditions: Rheumatoid Arthritis

Summary: the goal of this observational study is to learn about the long-term effects rheumatoid arthritis (ra) on cardiovascular system. the main question it aims to answer is: does seropositive raise risk of cardiovascular diseases more than seronegative ra ?

we will investigate cardiovascular risk factors in patients with seronegative and seropositive rheumatoid arthritis. complete clinical examination including blood pressure (bp; using an automatic bp monitor) and heart rate (in beats per minute (bpm) either from an automatic bp monitor or a 12 lead ecg) will be measured according to the standard hospital procedures. routine laboratory investigations, including complete blood count (cbc), blood parameters, including autoantibodies and lipid profile will be determined), liver and kidney function tests, erythrocyte sedimentation rate (esr), c-reactive protein (crp), and lipid profile panel will be recorded. the disease activity score-28 (das-28) and health assessment questionnaire (haq) will be assessed. framingham risk score will be calculated. carotid doppler will be done . current medications use including synthetic disease-modifying anti-rheumatic drugs (dmards), in addition to steroids, will be recorded. rheumatoid factor and anticitrullinated proteins antibodies presence will be determined. cardiovascular risk factors, including inflammation, hypertension, smoking, obesity, and dyslipidemia will be observed and a higher risk of cardiovascular diseases events (including myocardial infarction, stroke, and heart failure).

Eligibility criteria:
inclusion criteria: * adult patients ≥ 18 years. * both sexes. * all patients with ra confirmed using the 2010 american college of rheumatology/european alliance of associations for rheumatology eular classification criteria * ra diagnosed for at least six months to ensure chronicity. exclusion criteria: * diagnosis of other significant autoimmune diseases (e.g., lupus, scleroderma). * use of medications known to significantly affect cardiovascular outcomes (e.g., certain anticoagulants or anti-inflammatory agents) that are not part of standard ra treatment.